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Abstract: Patients with inherited dilated cardiomyopathy (DCM) often suffer from severe heart failure
based on impaired cardiac contractility leading to increased morbidity and mortality. Integrin-linked
kinase (ILK) as a part of the cardiac mechanical stretch sensor was found to be an essential genetic
regulator of cardiac contractility. Integrin-linked kinase localizes to z-disks and costameres in
vertebrate hearts and regulates the activity of the signaling molecule protein kinase B (PKB/Akt)
by controlling its phosphorylation. Despite identification of several potential drug targets in the
ILK signaling pathway, pharmacological treatment strategies to restore contractile function in
ILK-dependent cardiomyopathies have not been established yet. In recent years, the zebrafish
has emerged as a valuable experimental system to model human cardiomyopathies as well as
a powerful tool for the straightforward high-throughput in vivo small compound screening of
therapeutically active substances. Using the ILK deficient zebrafish heart failure mutant main squeeze
(msq), which shows reduced PKB phosphorylation and thereby impaired cardiac contractile force,
we identified here, in an automated small compound screen, the protein phosphatase inhibitors
calyculin A and okadaic acid significantly restoring myocardial contractile function by reconstituting
PKB phosphorylation in msq ILK-deficient zebrafish embryos.
Keywords: dilated cardiomyopathy; integrin-linked kinase-protein kinase B (ILK-PKB) signaling;
small chemical compounds; phosphatase inhibitors
1. Introduction
Dilated cardiomyopathy (DCM) is a life-threatening heart disease significantly contributing to
systolic heart failure and sudden cardiac death based on reduced cardiac contractility [1–4]. Molecular
and genetic studies have identified more than 30 different DCM disease genes, mainly coding for
proteins of the sarcomere, the cardiac Z-disc and the cytoskeleton [5].
To allow adaption of cardiac contractility on changing circulatory demands such as arterial blood
pressure or volume preload, the autoregulatory cardiac stretch sensor system translates biomechanical
strain of cardiomyocytes into activation of several signaling pathways regulating myocardial contractile
force in vertebrates. Congruously, mutations of genes coding for proteins of the cardiac mechanical
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stress sensor are known to cause DCM in humans [6,7]. However, the detailed genetic and molecular
underpinnings of this complex autoregulatory mechanism are not fully understood yet, but of high
clinical importance, since impaired adaption of cardiac contractility is considered to cause a sizeable
proportion of DCM-related heart failure cases in humans [2,6,8]. Genetic studies of cardiac stretch
sensor components in zebrafish, mice and humans identified the integrin-linked kinase (ILK) as
an essential regulator of cardiac contractility adaption on changing circulatory demands [7,9].
In a forward genetic screen, we identified the zebrafish DCM mutant main squeeze (msq), carrying
a mutation in the kinase domain of ILK (L308P), leading to reduced kinase activity and finally to a loss
of cardiac stretch sensor function. Accordingly, homozygous msq mutant embryos are characterized
by severely reduced ventricular pump function as well as by decreased expression levels of stretch
responsive genes such as the atrial natriuretic factor (anf ) and vascular endothelial growth factor (vegf ) [10].
Together with PINCH (particularly interesting Cys-His-rich protein) and β-parvin, ILK forms the
functional ILK-PINCH-parvin (IPP) complex (Figure 1) [11,12], which is a crucial element of the
cardiac stretch sensor [13,14]. Similar to the ILK-deficient msq mutant, ablation of β-parvin or PINCH
in wild-type zebrafish leads to severely reduced cardiac contractility emphasizing that ILK as well as
its interactors are essential regulators of ventricular pump function [15].
In vertebrates, ILK is mainly expressed in heart and skeletal muscle, where it interacts through
integrins with growth factor receptors and signaling molecules such as the protein kinase B (PKB) for
signal transduction from the extracellular matrix to the cytoplasm [16–20] (Figure 1). In line with this,
PKB phosphorylation as a downstream target of ILK is severely reduced in msq zebrafish. Remarkably,
overexpression of constitutive active PKB restores cardiac contractility of msq [10], indicating that PKB
phosphorylation is critical for regular heart function. However, efficient pharmacological approaches
to enhance PKB phosphorylation and activation have not been established yet, but might be crucial to
improve contractile performance in vivo.
Figure 1. Schematic illustration of the integrin-linked kinase-protein kinase B (ILK-PKB) signaling
pathway. Integrin-linked kinase forms, together with PINCH (particularly interesting Cys-His-rich
protein) and parvin, the ILK-PINCH-parvin (IPP) complex and mediates signals from the extracellular
matrix (ECM) to the cytoplasm through integrins. The phosphorylated downstream target PKB
facilitates the expression of stretch responsive genes such as the atrial natriuretic factor (anf ), thereby
effectively transducing signals from the cardiac stretch sensor. Reduced PKB phosphorylation in
ILK deficient main squeeze mutant zebrafish hearts was demonstrated to lead to impaired cardiac
contractility and heart failure [10]. In this context, the inhibition of protein phosphatases (PP) by
small chemical compounds that results in an increase of PKB phosphorylation might be a promising
therapeutic approach to treat ILK-associated cardiomyopathies.
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In recent years, the zebrafish has emerged as a powerful tool for high-throughput in vivo screening
of small chemical compounds allowing biomolecule evaluation with straightforward assessment
of essential cardiac parameters such as cardiac development, myocardial contractility and heart
rhythm [21–23]. Using the zebrafish as drug screening platform, we aimed to identify chemical
compounds rescuing heart failure in msq mutant embryos via maintenance of PKB phosphorylation.
Hence, by using our automated small compound screening platform, we identified two phosphatase
inhibitors, okadaic acid and calyculin A, to significantly improve ventricular pump function by
enhancing PKB phosphorylation in ILK-deficient msq mutant zebrafish embryos.
2. Material and Methods
2.1. Zebrafish Strains
Zebrafish care and breeding was performed as described before [24]. All procedures
and experiments in this study were carried out after appropriate institutional approvals
(Tierforschungszentrum (TFZ) Ulm University, No. 0183), which conform to the EU Directive
2010/63/EU. For all procedures, the zebrafish strain main squeeze, msq (M347), was used [10].
2.2. Genotyping, Western Blot Analysis, and RNA In Situ Hybridization
Genotyping of msq embryos was performed by polymerase chain reaction (PCR) analysis using
the satellite markers z7028 (fwd CAACACCAGCATAGCCATGT, rev TGTGACAAGGTCAGTGGAGC)
as well as z7504 (fwd AATTGGGCTGCGTTTCATAC, rev TTCCACCTCCTGTAACCTGC) after DNA
isolation of whole embryos. Protein extraction for Western blot analysis was performed from
whole zebrafish embryos. For immunoblotting the proteins were separated by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to a polyvinylidene fluoride
(PVDF) membrane. The blots were probed with the primary antibody anti-pPKB S347 (4058, NEB/Cell
Signaling, Danvers, MA, USA). Anti-pan-Cadherin (ab16505, Abcam, Cambridge, MA, USA) served
as loading control. Signals were detected by chemiluminescence (anti-rabbit-HRP). Ribonucleic acid
whole-mount in situ hybridization was used to detect expression of anf transcripts essentially as
described elsewhere [10].
2.3. Small Compound Screen and Functional Assessment in Main Squeeze Embryos
Small compound screening was performed using a modified phosphatase inhibitor library with
a total of 32 different small molecules (BML-2834, ENZO Life Sciences, Inc., Farmingdale, NY, USA
and BIOZOL GmbH, Eching, Germany, Table A1 in the Appendix A). At 48 h post fertilization
(hpf) stage-matched wild-type siblings and msq mutant embryos (divided based on the heart failure
phenotype) were individually transferred into a 96-well-plate and ten embryos (five mutants and
five siblings) tested and analyzed per compound using our established automated small compound
screening platform [21]. Small compounds were added with a final concentration of 10 µM except
for the compounds A1–A3. To avoid toxic side-effects of the protein phosphatase (PP1 and PP2A)
inhibitors, which are associated with tumor promotion as well as impaired liver and gastrointestinal
function in animals as well as humans, we applied concentrations for calyculin A (A1), cyclosporine A
(A2) and okadiac Acid (A3) referring to previous in vivo studies (A1: 0.1 µM, A2: 0.15 µM, A3: 0.75
µM) [25–27]. Dimethyl sulfoxide (DMSO) was used as a solvent control with a concentration of 0.1%.
Embryos were treated and incubated for 24 h and kept in an incubator at 29 ◦C. Since proper cardiac
development requires regular myocardial contractions, we expected an additional developmental
rescue effect in case of early drug treatment [28]. Hence, incubation period was extended from 4 to 96
hpf in the secondary drug screening for the compounds calyculin A, okadaic acid and cyclosporine A.
Impact of small molecules on cardiac contractile function was evaluated by video microscopic movies
of zebrafish hearts with the DM IRB (Leica, Wetzlar, Germany) microscope. The functional assessment
of cardiac contractility was carried out as described before [24,29]. Fractional shortening (FS) and
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ventricular diameters were measured with the help of the zebraFS software (http://www.benegfx.de).
Only data from experiments where fractional shortening for at least three embryos could be measured,
were included in statistical analysis.
2.4. Statistical Analysis
If not further specified, results are expressed as mean and standard deviation (mean ± S.D.).
Significance of differences of numeric values between two groups was calculated by t-test if normal
distribution with equal variance was given. Normal distribution was determined by Shapiro–Wilk test
and equal variance by Brown–Forsythe test. Numeric variables that were not normally distributed
were analyzed by Mann–Whitney rank sum test. A p-value <0.05 was considered significant. In case of
multiple testing per data-set p-value was adapted by the Bonferroni adjustment method. Statistical
assessment was performed with Excel (Version 2016, Microsoft Inc., Redmond, WA, USA) or XLStat
software (V 2016.02.28430, Addinsoft, New York, NY, USA).
3. Results
3.1. Primary Small Compound Screen Identifies Phosphatase Inhibitors Restoring Cardiac Contractility in
msq Zebrafish
By genetically and molecularly characterizing the zebrafish mutant main squeeze (msq),
we identified ILK to be crucial to guarantee cardiac contractile force by controlling PKB
phosphorylation and thereby its activity [10,15].
Since PKB activity is significantly reduced in msq embryos, we here performed drug screening
of a phosphatase inhibitor library containing 32 different compounds (Table A1 in the Appendix A)
solved in DMSO using our established automated screening platform [21] with the aim to restore PKB
phosphorylation and subsequently systolic ventricular pump function.
First, to study the impact of the solvent agent DMSO on cardiac contractility, we analyzed
fractional shortening in wild-type (wt) and msq zebrafish incubated with 0.1% DMSO. We found that
mean ventricular fractional shortening (FS) in wt treated with 0.1% DMSO was 53.2 ± 3.4% (n = 51)
compared to 15.3 ± 6.7% (n = 35; p < 0.001) in msq with DMSO (Figure 2C). These findings are in line
with previous reported data on ventricular FS in wt and msq zebrafish [10], indicating that cardiac
contractility is affected in neither wt nor msq zebrafish by the solvent agent DMSO.
Figure 2. msq mutants show cardiac edema and reduced contractile function. msq mutants can be
distinguished from their wild-type siblings at 48 h post fertilization (hpf). (A–C) Starting from this
developmental stage, msq show cardiac edema (B) compared to wild-type sibling (A) and significantly
decreased ventricular fractional shortening compared to wild-type controls at 72 hpf (C).
During small compound screening, as many as 8/32 (25.0%) compounds in wild-type zebrafish
and 8/32 (25.0%) compounds in msq mutants led to lethality of more than 50% of compound treated
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zebrafish embryos. Except for the tyrosine phosphatase inhibitor RK-682 (B6) that was lethal in msq,
and except for Deltamethrin (B12) that was lethal in wt zebrafish, all compounds leading to death
in wild-type zebrafish were also lethal in msq (Table A1). In both study groups, Endothall (B3) was
excluded from further statistical analysis, since more than 50% of zebrafish in the DMSO control group
died. Thus, fractional shortening data were available for 23 (71.9%) compounds applied in both groups,
wild-type siblings and mutant msq zebrafish embryos.
As shown in Figure 3A, none of the applied small compounds led to a significant increase of
ventricular FS in wild-type siblings compared to the DMSO control group (Figure 3A). By contrast,
3 out of 32 (9.4%) tested chemicals, namely A1 (calyculin A), A2 (cyclosporin A) and A3 (okadaic acid)
showed a significant improvement of ventricular FS in msq mutants compared to msq controls treated
with DMSO only at 72 hpf (Figure 3B). All other tested compounds did not show significant changes
in FS in msq compared to DMSO treated mutants.
Figure 3. Primary small compound screen in msq mutants revealed three compounds to reconstitute
fractional shortening (FS). Impact of tested compounds on ventricular fractional shortening in wild-type
siblings as well as msq mutants. The data for average fractional shortening are plotted only for the
compounds where at least three embryos could be quantified. (A) None of the embryos showed any
increase or decrease in the average fractional shortening in wild-type embryos, whereas (B) compound
A1, A2 and A3 results in significantly increased ventricular FS in msq mutants (*: Statistically significant,
**: Highly significant, +: Lethal). For the drugs’ names, please refer to the Table A1 in the Appendix A.
For msq mutants incubated with calyculin A, mean ventricular fractional shortening 24 h after
drug administration was 22.2 ± 10.7% compared to 12.0 ± 8.5% in the control group (p = 0.006).
Similarly, mean ventricular FS in msq mutants treated with Cyclosporine A was significantly higher
(26.3 ± 4.0%) compared to the control group (19.3 ± 3.5%; p = 0.023). For okadaic acid, we found that
mean ventricular FS in msq mutants was 43.0± 8.1% at 24 h after drug administration in comparison to
a mean ventricular FS of 19.3 ± 3.5% in controls (p < 0.001; Figure 3B). Next, we performed a detailed
investigation (secondary screen) of the three identified compounds, with the aim to get a more in-depth
understanding of the molecular underpinnings leading to significant increase of ventricular FS in
msq mutants.
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3.2. Calyculin A and Okadaic Acid Reconstitute Cardiac Contractility in msq Cardiomyopathy via Restored
PKB Phosphorylation
In order to confirm the findings of the primary drug screening and to evaluate the impact of
the three identified compounds on cardiac contractility and PKB phosphorylation in more detail,
we analyzed ventricular FS in wild-type siblings and msq mutants that were incubated with the
candidate compounds from 4 to 96 hpf compared to 48 to 72 hpf in the initial drug screening.
After 96 hpf, wild-type zebrafish treated with calyculin A present with ventricular FS of
43.6 ± 13.6% compared to 42.6 ± 12.7% in untreated wt embryos, indicating that calyculin A has
no adverse effects on cardiac contractility in the wild-type situation. Remarkably, the nearly abolished
cardiac contractility observed in untreated msq embryos (ventricular FS: 2.2 ± 5.3%) at 96 hpf was
significantly improved in msq mutants (25.4 ± 18.9%; p < 0.001) treated with calyculin A after extended
incubation time (Figure 4A). These data confirm the positive impact of calyculin A on ventricular FS in
msq mutants and furthermore suggests that earlier drug administration and longer drug treatment
leads to stable reconstitution of cardiac contractility also at 96 hpf.
Figure 4. Calyculin A reconstitutes contractile force, PKB phosphorylation and anf expression in
msq. (A) Ventricular FS of homozygous mutant msq embryos (msq−/−) in comparison to wild-type
(WT) zebrafish. Homozygous msq embryos treated with 100 nmol/L calyculin A during 4–96 hpf
displayed improved contractile force (25.4 ± 18.9% (p = 0.00015) compared to embryos incubated
with DMSO (2.2 ± 5.3%). (n.s.: Not significant) (B) Treatment of homozygous msq−/− embryos
with 100 nmol/L calyculin A displayed an increased PKB phosphorylation (pPKB) in comparison to
controls. In situ hybridization revealed that calyculin A treated homozygous msq−/− embryos (E)
show, in contrast to DMSO-treated wild-type zebrafish (C) and DMSO-treated msq−/− embryos (D),
an almost indistinguishable anf expression.
Next, we evaluated the molecular impact of calyculin A, which is known to inhibit protein
phosphatases such as PP1 and PP2A. For both, PP1 and PP2A, it has been shown that PKB is
a physiological target in different tissues leading to decreased PKB phosphorylation [25,30]. To examine
whether calyculin A improves cardiac contractility in msq zebrafish mutants via the reconstitution of
PKB phosphorylation, we performed immunoblotting assays to assess the PKB phosphorylation status
in msq mutants treated with calyculin A and their respective controls. Interestingly, we found that
untreated msq zebrafish present with a weak PKB phosphorylation (pPKB) signal, whereas calyculin A
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treated msq embryos displayed high pPKB levels comparable to wild-type zebrafish (Figure 4B). These
findings demonstrate that calyculin A treatment of ILK-deficient msq embryos effectively inhibits
further PKB dephosphorylation, thereby reconstituting phospho-PKB levels and rescuing cardiac
contractility in msq heart failure mutants.
To further reveal the effect of enhanced PKB activation by calyculin A on anf expression, which is
a final downstream target of ILK-PKB signaling, we performed anf specific whole-mount antisense
RNA in situ hybridizations. By in situ hybridization of individual msq embryos, we found that
treatment with calyculin A results in a significantly increased anf expression similar to the situation in
wild-type zebrafish (Figure 4C–E), further substantiating that calyculin A treatment is able to rescue
heart failure of msq mutants on a functional but also molecular level.
Similar to calyculin A, the fatty acid okadaic acid is also known to act as inhibitor of the protein
phosphatases PP1 and PP2A [30], insinuating that PKB phosphorylation might also be influenced by
this compound.
According to the extended calyculin A screening, we performed incubation of okadaic acid
in msq embryos from 4 to 96 hpf. Wild-type zebrafish treated with okadaic acid present with
a mean ventricular FS of 45.8 ± 8.2% and were indistinguishable from untreated wild-type embryos
(ventricular FS: 51.2± 4.4%; p >0.05) four days post compound administration (Figure 5A). As expected,
msq embryos of the DMSO-treated control group exhibited a mean ventricular FS of 2.0 ± 3.5%.
In contrast, okadaic acid treatment in msq led to significantly increased ventricular FS of 20.8 ± 19.9%
at 96 hpf (p = 0.01; Figure 5A).
Figure 5. Okadaic acid and cyclosporine A partially reconstitute the contractile force and PKB
phosphorylation in msq. (A) After treatment with 0.15 µmol/L okadaic acid during 4–96 hpf
homozygous msq−/− embryos showed an increased contractility from 2.0 ± 3.5% to 20.8 ± 19.9%.
(B) Immunoblotting indicated that the phosphorylation status of PKB (pPKB) was also slightly increased
in 0.15 µmol/L okadaic acid treated msq−/− embryos (incubation during 4–96 hpf). (C) Ventricular
fractional shortening of msq−/− embryos treated with 0.75 µmol/L cyclosporine A during 4–96 hpf
showed in comparison to DMSO-treated msq−/− embryos (7.9 ± 8.7%) a partially reconstituted
contractile force (16.9± 16.2%). (D) Correspondingly to fractional shortening, immunoblotting revealed
that treatment with 0.5 µmol/L cyclosporine A (incubation during 48–72 hpf) slightly increased the
level of phosphorylated PKB in msq−/− embryos compared to controls. (n.s.: Not significant).
Next, we performed immunoblotting assays in msq mutants after okadaic acid treatment to
determine the levels of PKB phosphorylation at 96 hpf (Figure 5B). Similar to calyculin A treatment,
PKB phosphorylation signal intensity was markedly higher in msq treated with okadaic acid compared
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to msq DMSO controls. Moreover, pPKB signal in okadaic acid treated msq embryos was comparable
to their wild-type controls, indicating that this compound is, similar to calyculin A, a strong inhibitor
of PKB dephosphorylation and therefore okadaic acid treatment preserved PKB phosphorylation in
msq mutants in vivo.
3.3. Cyclosporine A is a Poor Modulator of Ventricular Fractional Shortening and PKB Phosphorylation in msq
Mutants
In contrast to the compounds calyculin A and okadaic acid, which are known inhibitors of
the protein phosphatases PP1 and PP2A, cyclosporine A is considered to interfere only with PP2A,
implying that the impact of this compound on ventricular FS and PKB phosphorylation status in msq
might be different to the before-analyzed compounds. According to the secondary screen for calyculin
A and okadaic acid, we incubated wild-type zebrafish as well as msq mutants with cyclosporine A
from 4 to 96 hpf. For wild-type zebrafish treated with DMSO only and wild-type zebrafish treated
with cyclosporine A, we found no significant difference in ventricular FS (wt-DMSO: 48.5 ± 4.4% vs.
wt-cyclosporine A: 48.2 ± 6.0%; p = 0.911; Figure 5C). Remarkably, ventricular FS tends to be higher in
msq mutants after cyclosporine A treatment from 4 to 96 hpf (16.9± 16.2%, Figure 5C) compared to msq
controls (7.9 ± 8.7%; p = 0.137). However, level of statistical significance with p < 0.05 was not reached
in this experimental setting. In accordance, reconstitution of PKB phosphorylation in msq mutants was
less pronounced after cyclosporine A administration than in msq embryos treated with okadaic acid or
calyculin A (Figure 5D), indicating that cyclosporine A is a poor inhibitor of PKB dephosphorylation
and cardiac contractility in msq mutants.
4. Discussion
Integrin-linked kinase is a key molecule of the mechanical stretch sensor in the vertebrate heart,
regulating expression of stretch-responsive genes such as anf and vegf and thereby allowing adaption
of cardiac contractility to various hemodynamic demands. As shown in several genetic studies in
animal models as well as in humans, mutations in genes encoding for proteins of the mechanical
stretch sensor system lead to reduced ventricular FS and finally to dilated cardiomyopathy [2,6,8,10].
Based on a mutation within the kinase domain of ILK homozygous mutant msq embryos display
a progressive reduction of myocardial contractility. On molecular level, homozygous msq embryos are
characterized by a reduced PKB phosphorylation and a decreased expression of the stretch responsive
genes anf and vegf [10,15], making msq a suitable animal model for ILK-dependent DCM. Despite
detailed characterization of the ILK-PKB signaling pathway, pharmacological approaches to restore
ILK-PKB function are still missing.
With the aim to enhance ILK-PKB signaling pathway in msq, we studied the impact of 32 small
compounds derived from a phosphatase inhibitor library on ventricular FS in this heart failure
model. We hypothesized that the inhibition of dephosphorylation and consecutive inactivation of
PKB by phosphatase inhibitors might lead to restored ILK-PKB signaling and finally to reconstituted
cardiac contractility.
In our primary small compound screen using our recently established screening platform [21],
we evaluated 32 compounds and found three biomolecules, namely calyculin A, okadaic acid and
cyclosporine A significantly improving ventricular FS. Interestingly, these compounds are known to
act on the protein phosphatases PP1 and PP2A, which are essential regulators of the phosphorylation
status in numerous key signaling pathways [30–32]. Drug screening of other PP1/PP2A inhibitors such
as the compounds B1 (cantharidic acid) and B2 (cantharidin) led to lethality of both wild-type and msq
mutant embryos. We conclude that our straightforward small compound screening approach allows
to identify appropriate potential therapeutic biomolecules and to exclude substances with adverse
effects from further in vivo evaluation.
As observed in our secondary drug screening, we found that among the three identified
compounds calyculin A turned out to have the strongest effect on cardiac contractility and PKB
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phosphorylation. However, in contrast to okadaic acid, it has been shown that calyculin A inhibits
not only PP1 and PP2A but also the myosin light chain (MLC) phosphatase, which is an important
regulator of the contractile apparatus in the vertebrate heart [30]. Myosin light chain phosphatase
dephosphorylates the regulatory light chain of myosin II and initiates the relaxation process of muscle
cells. Whether the inhibition of MLC phosphatase by calyculin A also contributes to restoration of
ventricular FS in msq mutants was not analyzed in our experimental setting. However, we conclude
that, due to its pleiotropic effects in cardiomyocytes, calyculin A should be considered as a promising
biomolecule with the potential to treat ILK-dependent DCM.
Cyclosporine A is an effective immunosuppressive drug that has been prescribed for decades for
a vast number of patients, e.g., after organ transplantation to reduce graft-versus-host reactions.
In contrast to calyculin A and okadaic acid, cyclosporine A failed to significantly increase
ventricular FS in msq mutants despite recovered PKB phosphorylation. Hence, in our experimental
setting cyclosporine A occurred only as an intermediate mediator of the ILK-PKB signaling pathway in
comparison to calyculin A and okadaic acid. However, it is known that cyclosporine A has a beneficial
myocardial effect by attenuating detrimental hypertrophy of the left ventricle in mice undergoing
pressure overload [33]. Hence, based on the protective effect in cardiomyopathy model organisms
and the long-term experience with cyclosporine A in daily clinical routine, cyclosporine A is still an
interesting target for future investigations in the context of cardiomyopathies.
In recent years, the zebrafish has emerged as a powerful and reliable model organism for
the rapid and straightforward in vivo analysis of small molecule bioactivity for a broad range of
cardiovascular diseases. Advances in the field like fully-automated high-throughput screenings
will be of additional advantage, enabling testing of numerous biomolecules in an effective and
time-saving manner [23,34]. Although we show promising results of at least two compounds for
the treatment of genetic ILK-dependent cardiomyopathy in a vertebrate model, additional studies
in alternative model systems are needed to elucidate the transferability of our results to mammals
and humans.
In this context, human-induced-pluripotent-stem-cell-derived cardiomyocytes cells (hiPSC-CM)
have been successfully established in recent years for cardiovascular disease modeling as well as
drug screening. In contrast to animal models, hiPSC-CM are biologically identical to their human
donors, facilitating significantly the transferability of novel genetic and molecular findings. However,
hiPSC-CM differ in several important aspects from adult human cardiomyocytes, especially in terms of
maturation, gene expression or ion channel function, reducing their field of application [35]. In contrast,
large mammalian animal models for cardiomyopathies, such as dogs, render pathomechanistical
findings that are easy to transfer to humans based on the high interspecies homogeneities,
but large-scale drug screening in a cost and time saving manner is not applicable in this type of
model organism. Thus, we conclude that the different disease models, including cell-based approaches
as well as vertebrate and mammalian animal models, with their particular strengths and weaknesses,
should be seen as complementary in long-term drug discovery rather than exclusionary.
Limitations
Initial drug screening with 32 compounds was partly performed with an arbitrarily predefined
biomolecule concentration of 10 µM. This one-concentration-fits-all approach facilitates evaluating
numerous compounds in a short time. However, biological impact of compounds that were lethal
in our animal model might be overestimated and biological impact of compounds with no obvious
effect on ventricular FS might be underestimated in our experimental setting due to inappropriate
compound concentration.
5. Conclusions
Heart failure is one of the most frequent reasons for morbidity and mortality in developed
countries. Genetic variants in the ILK gene are associated with impaired cardiac contractility in
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humans. Aided by the ILK-deficient zebrafish heart failure mutant (msq), we identified in an automated
small compound screen the protein phosphatase inhibitors calyculin A and okadaic acid leading to
significantly restored pump function of the zebrafish heart via reconstituting PKB phosphorylation.
To evaluate the therapeutic potential of these promising small compounds in humans, calyculin A and
okadaic acid should be further investigated in mammalian model organisms.
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Appendix A
Table A1. Modified ENZO ® library of protein phosphatases inhibitors.
Plate Location Name Target Lethality
A1 Calyculin A PP1 and PP2A
A2 Cyclosporin A PP2A
A3 Okaid acid PP1 and PP2A
B1 Cantharidic acid PP1 and PP2A wt, msq
B2 Cantharidin PP1 and PP2A wt, msq
B3 Endothall PP2A
B4 Benzylphosphonic acid Tyrosine phosphatases
B5 L-p-Bromotetramisole oxalate Tyrosine phosphatases
B6 RK-682 Tyrosine phosphatases msq
B7 RWJ-60475 CD45 tyrosinephosphatase
B8 RWJ-60475 (AM)3
CD45 tyrosine
phosphatase (cell
permeable)
B9 Levamisole HCl Mammalian alkalinephosphatase
B10 Tetramisole HCl Mammalian alkalinephosphatase
B11 Cypermethrin Calcineurin (PP2B)
B12 Deltamethrin Calcineurin (PP2B) wt
C1 Fenvalerate Calcineurin (PP2B)
C2 Tyrphostin 8 Calcineurin (PP2B)
C5 BN-82002
C6 Shikonin
C7 NSC-663284 CDC25
C9 Pentamidine PRL1
C10 BVT-948 Tyrosine phosphatases
C11
1-(2-Bromobenzyloxy)-4-
bromo-2-benzylidene
rhodanine
PRL3
C12 Alexidine·2HCl PTPMT1 wt, msq
D1 9,10-Phenanthrenequinone CD45 tyrosinephosphatase wt, msq
D2 BML-260 JSP-1 wt, msq
D3 Sanguinarine chloride PP2C wt, msq
D4 BML-267 PTP1B
D5 BML-267 Ester PTP1B (cell permeable)
D6 OBA Tyrosine phosphatases
D7 OBA Ester Tyrosine phosphatases(cell permeable)
D8 Gossypol Calcineurin (PP2B) wt, msq
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